SUMMARY
Basal cell carcinoma (BCC) is the most common skin cancer in Caucasian population. Surgical excision is the gold standard treatment for BCC. Secondary surgical approach in patients presenting surgical scars after multiple surgical excisions or submitted to radiotherapy without obtaining a safe clearance margin, should be avoided. In recent years the use of electrochemotherapy (ECT) in head and neck cancers using intravenous bleomycin was specifically addressed and BCC resulted to be among tumors with the best response to ECT. We report a case of a recurrent nasal BCC treated with ECT with a complete regression of lesions after 8 weeks and a disease free period of 7 months. ECT is a good palliative treatment not affecting survival rate but improving quality of life in patients.
Financial competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.